Savara, Inc..
SVRA.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Savara, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for rare respiratory diseases. Their lead product candidate, Molgradex, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) being developed for autoimmun...Show More
Better Health for All
-10
Savara's core business is developing therapies for rare respiratory diseases, specifically autoimmune pulmonary alveolar proteinosis (aPAP).
1
Their lead product, MOLBREEVI, is in Phase 3 development and has demonstrated statistically significant improvements in pulmonary gas exchange, health-related quality of life, and reduced surfactant burden in clinical trials.
2
The company also sponsors a diagnostic testing program for aPAP, which helps reduce diagnosis delays.
3
These efforts indicate a strong positive health impact, addressing a serious condition with limited comparable therapies. As a clinical-stage company, it has no revenue from commercialized products, thus no harmful revenue. In clinical trials, MOLBREEVI was well-tolerated, with 97% of patients completing the double-blind period and no discontinuations due to drug-related adverse events.
4
The company's Expanded Access Program (EAP) for molgramostim is limited to eligible patients in select countries in North America and Europe, with expansion planned through 2026, and it received a Refusal to File letter from the FDA for its BLA.
5
The company's risk transparency is limited to general statements about SEC filings containing risk descriptions, rather than comprehensive public data on risks and benefits.
6
As a clinical-stage biopharmaceutical company, its entire R&D is focused on health improvement.
7
The company's health equity programs are limited to a third-party specialty pharmacy offering financial and insurance assistance, with 95.45% of patients served having no unresolved barriers at their annual assessment, but there is no evidence of direct funding or company-led programs.
8
Savara provides aPAP research updates and links to patient advocacy organizations for education.
9
While the company conducts clinical trials, there is no specific information on ethical conduct beyond general policy guidance.
Fair Money & Economic Opportunity
0
No evidence available to assess Savara, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
40
For fiscal year 2024, Savara Inc.'s CEO, Matthew Pauls, received a total compensation of $4,912,011.
1
The median employee pay was $490,319, resulting in a CEO pay ratio of 10:1.
2
Fair Trade & Ethical Sourcing
0
No specific, concrete data points were found in the provided articles to assess Savara, Inc. against any of the KPIs for Fair Trade & Ethical Sourcing. The articles primarily discuss executive compensation, corporate governance, internal ethics policies for employees, and regulatory matters related to drug applications. There is no information regarding supplier certifications, audit frequencies, forced or child labor incidents in the supply chain, supply chain traceability, remediation speed for supplier violations, ethical clauses in supplier contracts, high-risk material spend, or supplier diversity initiatives.
1
Honest & Fair Business
-40
Savara Inc. has a formal whistleblower policy that includes a third-party hotline and a web-based service for anonymous reporting.
1
However, there is no evidence provided regarding independent investigation processes. The company has adopted an anti-corruption policy that is compliant with the Foreign Corrupt Practices Act (FCPA) and explicitly addresses other anti-corruption laws, outlining prohibitions and reporting procedures.
2
There is no evidence provided regarding the frequency or effectiveness metrics of training for this policy.
Kind to Animals
0
Savara, Inc. engages in animal testing for medical analysis and clinical research.
1
No quantitative data is provided regarding the volume of animals used, the company's animal testing policy, or the extent of alternative testing methods.
2
No War, No Weapons
0
No specific, concrete evidence regarding Savara, Inc.'s association with arms manufacturing, military contracts, or conflict facilitation was found in the provided articles. The articles either indicated an inability to access content or provided only metadata about a report without its actual content, thus yielding no relevant facts for assessment.
Planet-Friendly Business
0
The provided articles do not contain specific, quantitative data points for any of the Planet-Friendly Business KPIs. The company's annual report explicitly states 'Not applicable' or 'No data provided' for environmental metrics such as emissions, renewable energy, water use, waste diversion, and environmental compliance.
1
While an 'ESG Summary' mentions a 'Reduced Greenhouse Gas Emissions Score' of 36.3,
2
this is an assessment score and not a direct measure of emissions (tCO₂e) or a specific reduction percentage against a baseline. Therefore, no KPIs can be scored based on the available evidence.
Respect for Cultures & Communities
0
No evidence available to assess Savara, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
The company's privacy policies outline user rights including access, rectification, erasure, objection, restriction, and data portability, with contact information for exercising these rights.
1
Data retention is limited to what is necessary for service provision, and call recordings for the medical information call center are retained for 90 days.
2
The company states compliance with GDPR and mentions data transfer safeguards.
3
No documented incidents of unauthorized data use have been reported.
4
While the company reports experiencing directed attacks, these have not materially impacted operations to date, and no data breaches have been disclosed.
5
The company conducts annual employee cybersecurity training, and its vulnerability management program includes penetration testing, vulnerability scanning, and red teaming, though specific metrics on effectiveness or coverage are not provided.
6
Zero Waste & Sustainable Products
0
No specific, concrete data points were found in the provided articles regarding Savara, Inc.'s waste management practices, product recyclability, packaging sustainability, use of recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certifications, waste disposal violations, material efficiency, packaging to product ratio, waste reduction targets, supplier waste requirements, or customer waste education programs.
1